Oxytocin induces the migration of prostate cancer cells: Involvement of the Gi-coupled signaling pathway

Molecular Cancer Research

Volumn 8, Issue 8, 2010, Pages 1164-1172

  Zhong, Miao ^a   Boseman, Maryam L ^a   Millena, Ana C ^a   Khan, Shafiq A ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYTOCIN; OXYTOCIN RECEPTOR; PERTUSSIS TOXIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; MALE; OXYTOCICS; OXYTOCIN; PEPTIDE FRAGMENTS; PERTUSSIS TOXIN; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, OXYTOCIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 77955722780     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0329     Document Type: Article

References (44)

1. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-83. (Pubitemid 32267075)
2. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994;269:27088-92. (Pubitemid 24982947)
3. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992;356:523-6.
4. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992;357:336-9.
5. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature 1992;356:526-9.
6. de Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994;356:215-20.
7. Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992;357:333-5.
8. Strakova Z, Soloff MS. Coupling of oxytocin receptor to G proteins in rat myometrium during labor: Gi receptor interaction. Am J Physiol 1997;272:E870-6.
9. Baek KJ, Kwon NS, Lee HS, Kim MS, Muralidhar P, Im MJ. Oxytocin receptor couples to the 80 kDa Gh α family protein in human myometrium. Biochem J 1996;315:739-44. (Pubitemid 26147597)
10. Sapino A, Cassoni P, Stella A, Bussolati G. Oxytocin receptor within the breast: biological function and distribution. Anticancer Res 1998;18:2181-6. (Pubitemid 28386486)
11. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 2004;11:871-85. (Pubitemid 40065559)
12. Cassoni P, Sapino A, Deaglio S, et al. Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res 2002;62:2406-13. (Pubitemid 34411725)
13. Arnaldi G, Gasc JM, de Keyzer Y, et al. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. J Clin Endocrinol Metab 1998;83:2029-35. (Pubitemid 28496333)
14. Cassoni P, Marrocco T, Bussolati B, et al. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 2006;4:351-9. (Pubitemid 44035154)
15. Reversi A, Rimoldi V, Marrocco T, et al. The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J Biol Chem 2005;280:16311-8.
16. Plecas B, Popovic A, Jovovic D, Hristic M. Mitotic activity and cell deletion in ventral prostate epithelium of intact and castrated oxytocin-treated rats. J Endocrinol Invest 1992;15:249-53.
17. Bodanszky M, Sharaf H, Roy JB, Said SI. Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol 1992;216:311-3.
18. Assinder SJ, Johnson C, King K, Nicholson HD. Regulation of 5α-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology 2004;145:5767-73. (Pubitemid 39564618)
19. Yamazaki T, Suzuki H, Tobe T, et al. Prostate adenocarcinoma producing syndrome of inappropriate secretion of antidiuretic hormone. Int J Urol 2001;8:513-6. (Pubitemid 32953826)
20. Cassoni P, Marrocco T, Sapino A, Allia E, Bussolati G. Evidence of oxytocin/oxytocin receptor interplay in human prostate gland and carcinomas. Int J Oncol 2004;25:899-904.
21. Whittington K, Assinder S, Gould M, Nicholson H. Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res 2004;318:375-82. (Pubitemid 39506506)
22. Einspanier A, Ivell R. Oxytocin and oxytocin receptor expression in reproductive tissues of the male marmoset monkey. Biol Reprod 1997;56:416-22. (Pubitemid 27081583)
23. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol 2005;173:342-59.
24. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984;44:3522-9. (Pubitemid 14098607)
25. Tahara A, Tsukada J, Tomura Y, et al. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells. Br J Pharmacol 2000;129:131-9. (Pubitemid 30072679)
26. Zigmond SH, Foxman EF, Segall JE. Chemotaxis assays for eukaryotic cells. Curr Protoc Cell Biol 2001;Chapter 12:Unit 12 1.
27. Kharait S, Dhir R, Lauffenburger D, Wells A. Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2006;343:848-56.
28. Millena AC, Reddy SC, Bowling GH, Khan SA. Autocrine regulation of steroidogenic function of Leydig cells by transforming growth factor-α. Mol Cell Endocrinol 2004;224:29-39. (Pubitemid 39194623)
29. Kimura T, Makino Y, Bathgate R, et al. The role of N-terminal glycosylation in the human oxytocin receptor. Mol Hum Reprod 1997;3:957-63. (Pubitemid 127509960)
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
31. Cattaneo MG, Chini B, Vicentini LM. Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 2008;153:728-36. (Pubitemid 351271756)
32. Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate 2007;67:1132-42. (Pubitemid 46983342)
33. Yin G, Zheng Q, Yan C, Berk BC. GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem 2005;280:27705-12. (Pubitemid 41076884)
34. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004;23:991-9. (Pubitemid 38250945)
35. Zhong M, Yang M, Sanborn BM. Extracellular signal-regulated kinase 1/2 activation by myometrial oxytocin receptor involves Gα(q)Gβγ and epidermal growth factor receptor tyrosine kinase activation. Endocrinology 2003;144:2947-56.
36. Singh SP, Anwer K, Wen Y, Sanborn BM. Inhibition of oxytocin-stimulated phosphoinositide turnover in rat myometrium by pertussis and cholera toxins may involve protein kinase A activation. Cell Signal 1992;4:619-25. (Pubitemid 23008829)
37. Dodge KL, Sanborn BM. Evidence for inhibition by protein kinase A of receptor/Gα(q)/phospholipase C (PLC) coupling by a mechanism not involving PLCβ2. Endocrinology 1998;139:2265-71.
38. Thackare H, Nicholson HD, Whittington K. Oxytocin - its role in male reproduction and new potential therapeutic uses. Hum Reprod Update 2006;12:437-48. (Pubitemid 43923416)
39. Neptune ER, Bourne HR. Receptors induce chemotaxis by releasing the βγ subunit of Gi, not by activating Gq or Gs. Proc Natl Acad Sci U S A 1997;94:14489-94.
40. Arai H, Tsou CL, Charo IF. Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: evidence that directed migration is mediated by βγ dimers released by activation of Gαi-coupled receptors. Proc Natl Acad Sci U S A 1997;94:14495-9. (Pubitemid 128617560)
41. Juneja J, Casey PJ. Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol 2009;158:32-40.
42. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007;120:3688-99. (Pubitemid 350120960)
43. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001;276:23341-8. (Pubitemid 37410717)
44. Schneider OD, Weiss AA, Miller WE. Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4. J Immunol 2009;182:5730-9.